Navigation Links
Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
Date:9/25/2007

Management rolls out new strategic platform for reducing risk of cancer

drug development

MILAN, Italy, Sept. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) held its 2007 annual shareholders meeting (Annual Meeting) on Tuesday, September 25, 2007 in Milan. The Company conducted the Annual Meeting in Milan since a majority of CTI's shares are held by Italian shareholders. At the 2007 Annual Meeting, shareholders re-elected Mary O. Mundinger, Dr. PH, and Jack W. Singer, M.D., as Class III Directors for a term to expire at the 2009 Annual Meeting. Frederick W. Telling, Ph.D., was elected as a Class II Director for a term expiring at the 2008 Annual Meeting. John H. Bauer was elected and Phillip M. Nudelman, Ph.D., was re-elected as Class I Directors for a term to expire at the 2010 Annual Meeting.

Also approved at the 2007 Annual Meeting were a proposal to approve the Company's 2007 Employee Stock Purchase Plan and reserve 250,000 shares of common stock for issuance under the Plan; a proposal to amend and restate the Company's 2003 Equity Incentive Plan, which was retitled as the 2007 Equity Incentive Plan; and a proposal to ratify Stonefield Josephson as CTI's independent auditor for the years ending December 31, 2006 and 2007.

"I'd like to thank our shareholders who voted or provided proxies for our meeting. I'm happy to report that as a result of focusing on outreach to our Italian shareholders and banks and sharing information with them about the process CTI is required to follow in the United States and under Washington law, of the approximately 27 million shares held in Italy, I believe more than two million of them have been voted dir
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... The Thomas Brain Health Center ... groundbreaking pilot study to see if early Alzheimer’s ... little as three to six months. , The ... medicine—will aggressively target and simultaneously treat the numerous ... brain. These include oxidative stress, neuroinflammation, mitochondrial dysfunction, ...
(Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
(Date:4/23/2015)... 2015 Glemser Technologies ... EMC® Enterprise Content Division (ECD) Certified Solution Partner ... Documentum® for Life Sciences Solution Suite . The ... capabilities to provide life sciences companies of all ... The EMC Documentum Solution Suite offers four modules: ...
(Date:4/23/2015)... 23, 2015 ReliantHeart's HeartAssist5® Ventricular Assist ... flow through the device) in real time, and this ... world’s leading provider of Machine to Machine (M2M) communications ... Flow via VADLink.com can be monitored by ... drop in flow below a minimum threshold, the patient ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... Data Presented Today at American Society of Clinical Oncology ... Therapeutics, Inc. today presented data demonstrating the use of ... cetuximab (ERBITUX(R)) on the colorectal cancer cells of individual ... the 54 primary colorectal cultures tested, eight percent were ...
... of response up to week 26 in moderate to ... infliximab. , , CHICAGO, June 1 New ... the Digestive Disease Week meeting demonstrate that Cimzia(R) (certolizumab ... week 26 for adult patients suffering from moderate to ...
... SOUTH PLAINFIELD, N.J., June 1 PTC Therapeutics, Inc. ... as Vice President of Commercial Operations. In this ... President, Commercial, and will be responsible for PTC,s patient ... reimbursement. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ...
Cached Biology Technology:Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 2Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 4Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 5Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 6Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 7Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 8Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 9Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 10PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations 2
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... School of Medicine of the University of Southern California ... female sex hormone, activates genes in breast-cancer cells. Greater ... lead to new treatments for the disease. ... Keck School,s Department of Biochemistry and Molecular Biology, was ...
... The TWAS 22nd General Meeting will take place on ... Theoretical Physics (ICTP), home to the Academy,s secretariat. TWAS,s ... by Romain Murenzi, executive director of TWAS; Fernando Quevedo, ... Affairs, Italy; and Jacob Palis, TWAS President, will highlight ...
... PARIS, Nov. 15, 2011 DigitalPersona, ... and endpoint protection solutions, today announced the availability ... biometric device manufacturers and solution providers. FingerJet OEM ... along with fast one-to-many identification and one-to-one verification. ...
Cached Biology News:USC researchers discover key aspect of process that activates breast cancer genes 2TWAS 22nd General Meeting in Trieste 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 3
...
Ezrin/Radixin/Moesin Antibody...
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... ADAMTS16 ( Abpromise for all ... Synthetic peptide based on the ... the amino acid sequence is proprietary) ... 170690 SWISS Protein ...
Biology Products: